Antisense Therapeutics (ASX:ANP) has commenced dosing in a muscular dystrophy mouse model of Duchenne muscular dystrophy to assess the potential clinical utility of ATL1102 in combination with dystrophin restoration drugs.
Antisense Therapeutics says dosing has commenced in combination study
September 12, 2022 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 5 September
September 5, 2025 - - Podcast -
Novartis ANZ appoints Marco Muscardo as ad-interim Country PresidentÂ
September 4, 2025 - - Latest News -
Australian industry looks to the UK as likely lesson for US 'Most Favored Nation'
September 4, 2025 - - Latest News -
Every new working group and every consultation squeezes more life out of reform, like a lemon wrung to its rind
September 4, 2025 - - Latest News -
The latest HTA Review report is a Dickensian tribute to policymaking and reform
September 3, 2025 - - Latest News -
Stakeholders could be mistaken for thinking the process is the point
September 3, 2025 - - Latest News -
Regulate the regulators - Why NDIS audit fees are failing providers and participants
September 3, 2025 - - Latest News